- Home
- SMTK vs PHGE Comparison
SMTK vs PHGE Comparison
Compare SMTK & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTK
- PHGE
- Stock Information
- Founded
- SMTK 2009
- PHGE 2015
- Country
- SMTK United Kingdom
- PHGE Israel
- Employees
- SMTK N/A
- PHGE N/A
- Industry
- SMTK
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- SMTK
- PHGE Health Care
- Exchange
- SMTK NYSE
- PHGE Nasdaq
- Market Cap
- SMTK 13.3M
- PHGE 14.6M
- IPO Year
- SMTK N/A
- PHGE N/A
- Fundamental
- Price
- SMTK $1.15
- PHGE $0.56
- Analyst Decision
- SMTK
- PHGE Strong Buy
- Analyst Count
- SMTK 0
- PHGE 2
- Target Price
- SMTK N/A
- PHGE $23.00
- AVG Volume (30 Days)
- SMTK 31.6K
- PHGE 59.8K
- Earning Date
- SMTK 05-13-2025
- PHGE 05-15-2025
- Dividend Yield
- SMTK N/A
- PHGE N/A
- EPS Growth
- SMTK N/A
- PHGE N/A
- EPS
- SMTK N/A
- PHGE N/A
- Revenue
- SMTK $105,000.00
- PHGE N/A
- Revenue This Year
- SMTK N/A
- PHGE N/A
- Revenue Next Year
- SMTK N/A
- PHGE N/A
- P/E Ratio
- SMTK N/A
- PHGE N/A
- Revenue Growth
- SMTK 854.54
- PHGE N/A
- 52 Week Low
- SMTK $1.56
- PHGE $0.48
- 52 Week High
- SMTK $13.00
- PHGE $4.99
- Technical
- Relative Strength Index (RSI)
- SMTK N/A
- PHGE 48.59
- Support Level
- SMTK N/A
- PHGE $0.50
- Resistance Level
- SMTK N/A
- PHGE $0.59
- Average True Range (ATR)
- SMTK 0.00
- PHGE 0.04
- MACD
- SMTK 0.00
- PHGE -0.00
- Stochastic Oscillator
- SMTK 0.00
- PHGE 48.20
About SMTK SMARTKEM INC
SmartKem Inc focuses on the design, development, industrialization, and technology transfer of low-temperature, solution-deposited organic semiconductors for transistor backplanes. The company's semiconductor platform can be used in a number of applications including mini-LED displays, AMOLED displays, fingerprint sensors, and logic circuits. The company derives revenue from the sale of TRUFLEX inks and demonstration products.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).